Order Article Reprints

Dzinamarira T, Almehmadi M, Alsaiari AA, Allahyani M, Aljuaid A, Alsharif A, Khan A, Kamal M, Rabaan AA, Alfaraj AH, et al. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina. 2023; 59(6):1041. https://doi.org/10.3390/medicina59061041

Dzinamarira, Tafadzwa, Mazen Almehmadi, Ahad Amer Alsaiari, Mamdouh Allahyani, Abdulelah Aljuaid, Abdulaziz Alsharif, Abida Khan, Mehnaz Kamal, Ali A. Rabaan, Amal H. Alfaraj, and et al. 2023. "Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection" Medicina 59, no. 6: 1041. https://doi.org/10.3390/medicina59061041

Dzinamarira, T., Almehmadi, M., Alsaiari, A. A., Allahyani, M., Aljuaid, A., Alsharif, A., Khan, A., Kamal, M., Rabaan, A. A., Alfaraj, A. H., AlShehail, B. M., Alotaibi, N., AlShehail, S. M., & Imran, M. (2023). Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection. Medicina, 59(6), 1041. https://doi.org/10.3390/medicina59061041